Product Description
Mechanisms of Action: ADRB2 Inhibitor
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: Ocular, Topical, Ophthalmic
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sylentis S.A.U.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Glaucoma, Open-Angle|Hypertension|Glaucoma
Phase 1: Glaucoma|Hypertension
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00990743 |
CUNFI-0511-0814 | P1 |
Completed |
Glaucoma|Hypertension |
2010-06-01 |
2019-03-19 |
Treatments |
|
2013-002947-27 |
SYLTAG | P2 |
Completed |
Glaucoma |
2015-08-05 |
2025-07-02 |
Treatments |
|
NCT02250612 |
SYLTAG | P2 |
Completed |
Glaucoma, Open-Angle|Hypertension |
2015-08-01 |
2020-11-05 |
||
NCT01739244 |
SYL040012_III | P2 |
Completed |
Hypertension|Glaucoma, Open-Angle |
2013-05-01 |
2019-03-19 |
Treatments |
|
2011-001849-33 |
2011-001849-33 | P2 |
Completed |
Hypertension|Glaucoma, Open-Angle |
2013-04-30 |
2022-03-13 |
Treatments |
|
NCT01227291 |
SYL040012_II | P2 |
Completed |
Hypertension|Glaucoma |
2012-03-01 |
2019-03-19 |
Treatments |